XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses:        
Research and development $ 3,260,938 $ 1,116,911 $ 28,196,970 $ 3,495,477
General and administrative 2,824,589 1,208,097 16,004,308 3,338,279
Total operating expenses 6,085,527 2,325,008 44,201,278 6,833,756
Loss from operations (6,085,527) (2,325,008) (44,201,278) (6,833,756)
Interest expense, net (12,459) (299,943) (168,239) (888,827)
Merger transaction costs (7,499,353)
Change in fair value of warrants 7,613 14,428
Change in fair value of convertible promissory notes (1,280,000) 48,468,678 (49,122,865)
Change in fair value of written call option derivative liabilities 206,150 (7,064)
Loss on issuance of commitment shares (890,000)
Net loss (5,884,223) (3,904,951) (4,282,828) (56,845,448)
Net loss attributable to common stockholders, basic (5,909,428) (3,904,951) (864,521) (56,845,448)
Net loss attributable to common stockholders, diluted $ (5,909,428) $ (3,904,951) $ (864,521) $ (56,845,448)
Net loss per share attributable to common stockholders, basic $ (0.03) $ (0.03) $ (0.01) $ (2.30)
Net loss per share attributable to common stockholders, diluted $ (0.03) $ (0.03) $ (0.01) $ (2.30)
Weighted-average common stock outstanding, basic 170,174,533 119,999,989 160,000,569 24,752,000
Weighted-average common stock outstanding, diluted 170,174,533 119,999,989 160,000,569 24,752,000